Gland Pharma Limited

rs 25

RMA LIMITED May 18, 2023 BSE Limited Corporate Relationship Department Phiroze Jeejeebhoy Towers 25th floor, Dalal Street Mumbai - 400 001 Scrip Code: 543245 National Stock Exchange of India Limi

32%

ations (INR Mn) 11,030 7,850 44,007 36,246 EBITDA (1) / EBITDA Margin (2) (INR Mn / %) 3,484 32% 1,684 21% 15,102 34% 10,248 28% Q4 FY22 Q4 FY23 FY22 FY23 Q4 FY22 Q4 FY23 FY22 FY23

21%

Mn) 11,030 7,850 44,007 36,246 EBITDA (1) / EBITDA Margin (2) (INR Mn / %) 3,484 32% 1,684 21% 15,102 34% 10,248 28% Q4 FY22 Q4 FY23 FY22 FY23 Q4 FY22 Q4 FY23 FY22 FY23 PBT / PAT /

34%

7,850 44,007 36,246 EBITDA (1) / EBITDA Margin (2) (INR Mn / %) 3,484 32% 1,684 21% 15,102 34% 10,248 28% Q4 FY22 Q4 FY23 FY22 FY23 Q4 FY22 Q4 FY23 FY22 FY23 PBT / PAT / PAT Margin (3

28%

36,246 EBITDA (1) / EBITDA Margin (2) (INR Mn / %) 3,484 32% 1,684 21% 15,102 34% 10,248 28% Q4 FY22 Q4 FY23 FY22 FY23 Q4 FY22 Q4 FY23 FY22 FY23 PBT / PAT / PAT Margin (3) (INR Mn / %

26%

/ PAT / PAT Margin (3) (INR Mn / %) R&D Expenses / (R&D % of Revenue) (INR Mn / %) 3,805 2,859 26% 29% 1,112 787 28% 10% 16,186 12,117 28% 10,546 7,810 22% 5.07% 1.05% 559 116 4.02%

29%

T / PAT Margin (3) (INR Mn / %) R&D Expenses / (R&D % of Revenue) (INR Mn / %) 3,805 2,859 26% 29% 1,112 787 28% 10% 16,186 12,117 28% 10,546 7,810 22% 5.07% 1.05% 559 116 4.02% 443

10%

NR Mn / %) R&D Expenses / (R&D % of Revenue) (INR Mn / %) 3,805 2,859 26% 29% 1,112 787 28% 10% 16,186 12,117 28% 10,546 7,810 22% 5.07% 1.05% 559 116 4.02% 443 8.63% 0.95% 678 75

22%

nue) (INR Mn / %) 3,805 2,859 26% 29% 1,112 787 28% 10% 16,186 12,117 28% 10,546 7,810 22% 5.07% 1.05% 559 116 4.02% 443 8.63% 0.95% 678 75 7.68% 603 5.17% 2,273 0.78% 342 1

5.07%

(INR Mn / %) 3,805 2,859 26% 29% 1,112 787 28% 10% 16,186 12,117 28% 10,546 7,810 22% 5.07% 1.05% 559 116 4.02% 443 8.63% 0.95% 678 75 7.68% 603 5.17% 2,273 0.78% 342 1,932 4

1.05%

/ %) 3,805 2,859 26% 29% 1,112 787 28% 10% 16,186 12,117 28% 10,546 7,810 22% 5.07% 1.05% 559 116 4.02% 443 8.63% 0.95% 678 75 7.68% 603 5.17% 2,273 0.78% 342 1,932 4.39% 5

4.02%

59 26% 29% 1,112 787 28% 10% 16,186 12,117 28% 10,546 7,810 22% 5.07% 1.05% 559 116 4.02% 443 8.63% 0.95% 678 75 7.68% 603 5.17% 2,273 0.78% 342 1,932 4.39% 5.56% 0.47% 2,01

Corporate Office

2

Regd. Office

1

Delivery Systems

1

Therapeutic Areas

1

Present in

1

Focused on

1

Regd. Office

Survey N o . 143-148, 1 5 0 & 151, N e a r Gandimaisamma ‘X’ Roads Survey N o . 143-148, 1 5 0 & 151, N e a r Gandimaisamma ‘X’ Roads Survey N o . 143-148, 1 5 0 & 151, N e a r Gandimaisamma ‘X’ Roads D.P. Pally, Dundigal, Dundigal-Gandimaisamma Mandal D.P. Pally, Dundigal, Dundigal-Gandimaisamma Mandal D.P. Pally, Dundigal, Dundigal-Gandimaisamma Mandal Medchal-Malkajgiri District, Hyderabad 500043, Telangana, Medchal-Malkajgiri District, Hyderabad 500043, Telangana, Medchal-Malkajgiri District, Hyderabad 500043, Telangana, Tel: +91-40-30510999 Fax: +91-40-30510800 Tel: +91-40-30510999 Fax: +91-40-30510800 Tel: +91-40-30510999 Fax: +91-40-30510800 India India India

Corporate Office

Plot N o . 11 & 84, T S I I C Phase: I V Plot N o . 11 & 84, T S I I C Phase: I V Plot N o . 11 & 84, T S I I C Phase: I V Pashamylaram (V), Patancheru (M), Sangareddy District Pashamylaram (V), Patancheru (M), Sangareddy District Pashamylaram (V), Patancheru (M), Sangareddy District Hyderabad 502307, Telangana, India Hyderabad 502307, Telangana, India Hyderabad 502307, Telangana, India Tel: +91-8455-699999 Tel: +91-8455-699999 Tel: +91-8455-699999 CIN: L24239TG1978PLC002276 | email: gland@glandpharma.com; investors@glandpharma.com | www.glandpharma.com CIN: L24239TG1978PLC002276 | email: gland@glandpharma.com; investors@glandpharma.com | www.glandpharma.com CIN: L24239TG1978PLC002276 | email: gland@glandpharma.com; investors@glandpharma.com | www.glandpharma.com GLAND PHARMA LIMITED Gland Pharma Limited Financial Results Q4’FY23 & FY23 18th May 2023 Cemcitibii lajectiM ■ Safe Harbor Statement The Presentation is to provide the general background information about the Company’s activit

Therapeutic Areas

• Anti-diabetic • Neurological and Central • Anti-infectives • Anti-malarials • Anti-neoplastics (Oncology) • Blood-related • Cardiac • Gastro-intestinal • Hormones Nervous System • Ophthalmics and Otologicals • Pain, neuro-muscular blocking agents & analgesics • Respiratory • Vitamins, minerals & nutrients Centralized R&D Laboratory located at Dundigal, Hyderabad facility, with supporting personnel at each manufacturing facility ~350 personnel team including PhDs, pharmacy post graduates and chemists New R&D building at Pashamylaram, Hyderabad R&D expertise supports regulatory filings globally Regulatory Track Record • 334 ANDA Filings in US – 263 approved; 71 pending (1) ̶ Of 334, 157 owned by Gland Pharma out of which 113 are approved and 44 are pending for approval 248 for sterile injectables, 53 for oncology and 33 for ophthalmics related products • 1,601 product registrations globally, of which 455 in United States, Europe, Canada, Australia and New Zealand, 70 in India and 1076

Present in

▪ Oncology ▪ Ophthalmics and Otologicals ▪ Blood-related ▪ Neurological and Central Nervous System ▪ Pain, neuro-muscular agents and analgesics

Focused on

▪ Complex injectables ▪ NCE-1s ▪ First-to-File products Expanding capabilities in: Expanding in new delivery systems: Key products include: ▪ Peptides ▪ Pens ▪ Long-acting injectables ▪ Suspensions ▪ Cartridges ▪ Cis-Atracurium Besylate ▪ Enoxaparin Sodium ▪ Heparin Sodium ▪ Rocuronium Bromide ▪ 505(b)(2) filings ▪ Hormonal products ▪ Biosimilar Significant R&D Investment Translating into Revenue From New Launches Centralized R&D team of c.315 members including PhDs, pharmacy post graduates and chemists Track record of coming up with new complex products 3.8% 4.7% 3.5% 3.5% 5.2% 2,273 5.5% 2,014 966 922 1,220 615 22% 13% 9% 11% 5% 4% 58 3,493 45 51 2,717 2,292 52 3,660 44 35 2,360 1,410 FY18 FY19 FY20 FY21 FY22 FY23 FY18 FY19 FY20 FY21 FY22 FY23 Total R&D expenditure (₹mn) Revenue from new product launch (₹mn) R&D expenditure as % of revenue from operations As % of revenue from operations # products launched 26 IGLAND] …Supported by Proven Regulatory Capabilities Product Development Ca

Corporate Office

Gland Pharma Limited Plot No. 11 & 84, TSIIC Phase: IV Pashamylaram (V), Patancheru (M), Sangareddy District Hyderabad 502307, Telangana, India BSE 543245 ®NSE GLAND Bloomberg GLAND:IN 35